For startups
FDA-Stage Finance. Investor-Grade Reporting.
We help medical device, pharma, and healthcare companies build the financial infrastructure that supports regulatory milestones and investor confidence — at the same time.
Industry Context
The Financial Complexity of Regulated Growth
Regulatory timelines, clinical costs, and life science investors require a specialized finance approach that generalist firms can't provide.
01
FDA Pathway Cost Planning
We build financial models that accurately reflect 510(k), De Novo, or PMA pathway costs, timeline risk, and capital requirements — giving investors a defensible plan.
02
Board Reporting Setup
We build accounting infrastructure to accurately track SBIR, NIH, and DOD grant spend — keeping you compliant and your commercialization story clean.
03
CFO-on-Demand
We build board packages and investor updates structured around the milestones and metrics life science investors track.
Services
The Full CFO Finance Function, Built for Regulated Industries
Medical device and pharma companies face financial challenges that general finance firms are not equipped to handle. Regulatory timelines, clinical costs, and life science investors all require a specialized approach.
CFO Services
Fractional CFO for Health & MedTech
A U.S.-based CFO who understands the regulatory lifecycle and life science capital markets — representing your financial position with the credibility your sector demands
Financial Modeling
Regulatory Cost & Capital Modeling
Detailed financial models covering the regulatory pathway, clinical trial costs, and commercialization milestones — with scenario modeling for timeline risk.
Reporting
Board & Investor Reporting
Monthly board packages structured around regulatory milestones, spend vs. budget, and runway — designed to reinforce investor confidence between rounds.
Compliance
GAAP Compliance & Audit Readiness
GAAP-compliant accounting — including revenue recognition, R&D capitalization, and grant accounting — built to withstand institutional investor and auditor scrutiny.
Case Study · Medical Device
$15M Series A: Medical Device Company Gets Board-Ready in Weeks
Adea rebuilt a medical device startup's financial infrastructure and prepared a complete investor package — 90 days before their Series A close — and the round closed on schedule.
Outcome
$15M
Series A Raised
90
Days to Close
4
Weeks to Investor-Ready